Comparable stake leader
MARSHALL WACE, LLP
SEC ownership of InspireMD, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001433607.
Disclosed value leader
MARSHALL WACE, LLP
Comparable rows
46/50
Latest evidence
27 May 2026
- Public ticker
- NSPR on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
MARSHALL WACE, LLP
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
46 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
MARSHALL WACE, LLP
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
27 May 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001433607
- Issuer location
- Miami, FL
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of InspireMD, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
MARSHALL WACE, LLP
Disclosed value leader
MARSHALL WACE, LLP
Comparable rows
46/50
Latest evidence
27 May 2026
13D/G
13F
3/4/5
Lead comparable stake: 10%
4 rows are not safely comparable across share classes.
13D/G row: MARSHALL WACE, LLP
Showing 1-8 of 50 holder rows.
Quick read
MARSHALL WACE, LLP leads the comparable SEC ownership view at 10%.
46 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens MARSHALL WACE, LLP's linked filing trail.
Comparable ownership
Top 5
MARSHALL WACE, LLP
10%
Nantahala Capital Management, LLC
10%
Rosalind Advisors, Inc.
9.2%
Michael A. Lawless
8.6%
Aberdeen Group plc
7.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| MARSHALL WACE, LLP |
13D/G
13F
Company
|
10%
|
$67,729,915
28,103,699 shares
|
$0 | 30 Sep 2025 |
| Nantahala Capital Management, LLC |
13D/G
13F
Company
|
10%
|
$6,458,327
4,819,647 shares
|
+$755,650 | 31 Mar 2026 |
| Rosalind Advisors, Inc. |
13D/G
13F
Company
|
9.2%
|
$19,557,045
10,987,104 shares
|
$0 | 31 Dec 2025 |
| Michael A. Lawless |
13D/G
3/4/5
Chief Financial Officer
|
8.6%
|
$8,711,502
3,614,731 shares
|
$0 | 26 Jun 2025 |
| Aberdeen Group plc |
13D/G
13F
Company
|
7.5%
|
$5,648,588
3,173,364 shares
|
+$1,232,200 | 31 Dec 2025 |
| ORBIMED ADVISORS LLC |
13D/G
13F
Company
|
7.4%
|
$5,577,461
3,133,405 shares
|
+$1,780,000 | 31 Dec 2025 |
| Parkman Healthcare Partners LLC |
13D/G
13F
Company
|
5.8%
|
$5,881,926
2,440,633 shares
|
$0 | 30 Sep 2025 |
| Nantahala Capital Partners Limited Partnership |
13D/G
|
5.7%
|
$5,827,419
2,418,016 shares
|
$0 | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$293,749.
Buys
$420,762
Insiders: 4
Sells
$127,013
Insiders: 1
Net
+$293,749
Shares: +263,202
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 350,115
Shares: 86,913
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 66,000 | 22,778 | $71,925 | $23,006 | +$48,919 |
| 3-6 | 252,771 | 0 | $293,997 | $0 | +$293,997 |
| 6-9 | 31,344 | 64,135 | $54,840 | $104,007 | -$49,167 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-15 of 15 reporting-owner rows connected to InspireMD, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
15
Largest Forms 3/4/5 holder
Marvin Slosman
Net 12M change
+$293,750
Latest report
27 May 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Marvin Slosman | CEO and President, Director | $4,267,989 | +$25,200 | +0.59% | Filing P/S | 12 May 2026 |
| Craig Shore | CFO and CAO | $2,226,709 | Mixed | 07 Jan 2025 | ||
| Andrea Tommasoli | Chief Operating Officer | $1,698,812 | Mixed | 14 Jan 2026 | ||
| Paul Stuka | Director | $1,275,024 | +$186,725 | +17% | Mixed | 27 May 2026 |
| Michael A. Lawless | Chief Financial Officer | $1,231,217 | Mixed | 14 Jan 2026 | ||
| Thomas J. Kester | Director | $1,105,160 | Mixed | 15 Sep 2025 | ||
| Shane Thomas Gleason | Chief Commercial Officer | $1,064,420 | -$127,013 | -11% | Filing P/S | 15 Jan 2026 |
| Michael Berman | Director | $1,063,692 | Mixed | 14 Jan 2026 | ||
| Gary S. Roubin | Director | $984,684 | +$106,200 | +12% | Filing P/S | 07 May 2026 |
| Kathryn Arnold | Director | $584,957 | Mixed | 30 Dec 2025 | ||
| Patrick Verta | EVP Clinical/Medical Affairs | $578,187 | Mixed | 07 Jan 2025 | ||
| Scott R. Ward | Director | $272,660 | +$102,638 | +60% | Filing P/S | 06 May 2026 |
| Danny L. Dearen | Director | $181,643 | Mixed | 14 Jan 2026 | ||
| Raymond W. Cohen | Director | $164,502 | Mixed | 14 Jan 2026 | ||
| Campbell Rogers | Director | $70,761 | Mixed | 13 Oct 2021 |
Recent insider transactions for InspireMD, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Paul Stuka | NSPR | Common Stock | Purchase | 3.09% | $17,500 | $0.8750 | 20,000 | 667,871 | 27 May 2026 | Direct |
| Shane Thomas Gleason | NSPR | Common Stock | Sale | -2.12% | $23,006 | $1.01 | -22,778 | 1,053,882 | 19 May 2026 | Direct |
| Paul Stuka | NSPR | Common Stock | Purchase | 0.78% | $5,750 | $1.15 | 5,000 | 647,871 | 14 May 2026 | Direct |
| Paul Stuka | NSPR | Common Stock | Purchase | 1.58% | $11,575 | $1.16 | 10,000 | 642,871 | 13 May 2026 | Direct |
| Marvin Slosman | NSPR | Common Stock | Purchase | 0.59% | $25,200 | $1.20 | 21,000 | 3,556,658 | 12 May 2026 | Direct |
| Paul Stuka | NSPR | Common Stock | Purchase | 1.61% | $11,900 | $1.19 | 10,000 | 632,871 | 11 May 2026 | Direct |
| Paul Stuka | NSPR | Common Stock | Purchase | 11.8% | $76,126 | $1.16 | 65,626 | 622,871 | 08 May 2026 | Direct |
| Scott R. Ward | NSPR | Common Stock | Purchase | 44.7% | $84,243 | $1.15 | 73,255 | 237,096 | 07 May 2026 | Direct |
| Paul Stuka | NSPR | Common Stock | Purchase | 1.21% | $7,335 | $1.15 | 6,378 | 531,599 | 07 May 2026 | Direct |
| Gary S. Roubin | NSPR | Common Stock | Purchase | 12.1% | $106,200 | $1.18 | 90,000 | 834,478 | 07 May 2026 | Direct |
| Scott R. Ward | NSPR | Common Stock | Purchase | 10.8% | $18,394 | $1.15 | 15,995 | 163,841 | 06 May 2026 | Direct |
| Paul Stuka | NSPR | Common Stock | Purchase | 0.29% | $1,699 | $1.12 | 1,517 | 525,221 | 06 May 2026 | Direct |
| Shane Thomas Gleason | NSPR | Common Stock | Sale | -0.27% | $4,676 | $1.59 | -2,941 | 1,076,660 | 02 Feb 2026 | Direct |
| Shane Thomas Gleason | NSPR | Common Stock | Sale | -0.18% | $3,208 | $1.60 | -2,000 | 1,139,177 | 02 Feb 2026 | Direct |
| Shane Thomas Gleason | NSPR | Common Stock | Sale | -0.25% | $4,730 | $1.63 | -2,900 | 1,141,177 | 30 Jan 2026 | Direct |
| Shane Thomas Gleason | NSPR | Common Stock | Sale | -0.44% | $8,250 | $1.65 | -5,000 | 1,144,077 | 29 Jan 2026 | Direct |
| Shane Thomas Gleason | NSPR | Common Stock | Sale | -1.07% | $20,464 | $1.65 | -12,395 | 1,149,077 | 28 Jan 2026 | Direct |
| Shane Thomas Gleason | NSPR | Common Stock | Sale | -0.41% | $7,956 | $1.66 | -4,781 | 1,161,472 | 27 Jan 2026 | Direct |
| Shane Thomas Gleason | NSPR | Common Stock | Sale | -0.72% | $13,239 | $1.57 | -8,411 | 1,166,253 | 22 Jan 2026 | Direct |
| Shane Thomas Gleason | NSPR | Common Stock | Sale | -1.48% | $28,553 | $1.62 | -17,593 | 1,174,664 | 21 Jan 2026 | Direct |
| Shane Thomas Gleason | NSPR | Common Stock | Sale | -0.25% | $4,710 | $1.59 | -2,955 | 1,192,257 | 20 Jan 2026 | Direct |
| Shane Thomas Gleason | NSPR | Common Stock | Sale | -0.19% | $3,627 | $1.61 | -2,250 | 1,195,212 | 16 Jan 2026 | Direct |
| Shane Thomas Gleason | NSPR | Common Stock | Sale | -0.24% | $4,593 | $1.58 | -2,909 | 1,197,462 | 15 Jan 2026 | Direct |
| Scott R. Ward | NSPR | Common Stock | Award | 147.3% | 88,053 | 147,846 | 14 Jan 2026 | Direct | ||
| Andrea Tommasoli | NSPR | Common Stock | Award | 31.2% | 226,695 | 954,389 | 14 Jan 2026 | Direct | ||
| Paul Stuka | NSPR | Common Stock | Award | 33.7% | 132,076 | 523,704 | 14 Jan 2026 | Direct | ||
| Marvin Slosman | NSPR | Restricted Stock Units | Award | 46% | 1,114,792 | 3,535,658 | 14 Jan 2026 | Direct | ||
| Gary S. Roubin | NSPR | Common Stock | Award | 13.4% | 88,053 | 744,478 | 14 Jan 2026 | Direct | ||
| Michael A. Lawless | NSPR | Common Stock | Award | 48.8% | 226,695 | 691,695 | 14 Jan 2026 | Direct | ||
| Shane Thomas Gleason | NSPR | Common Stock | Award | 60.7% | 453,390 | 1,200,371 | 14 Jan 2026 | Direct | ||
| Danny L. Dearen | NSPR | Common Stock | Award | 75.9% | 44,030 | 102,047 | 14 Jan 2026 | Direct | ||
| Raymond W. Cohen | NSPR | Common Stock | Award | 91% | 44,030 | 92,417 | 14 Jan 2026 | Direct | ||
| Michael Berman | NSPR | Common Stock | Award | 33.3% | 88,053 | 352,586 | 14 Jan 2026 | Direct | ||
| Kathryn Arnold | NSPR | Common Stock | Award | 22.4% | 55,556 | 303,087 | 30 Dec 2025 | Direct | ||
| Kathryn Arnold | NSPR | Options to purchase common stock (right to buy) | Award | 30.9% | 26,276 | 111,221 | 30 Dec 2025 | Direct | ||
| Paul Stuka | NSPR | Common Stock | Purchase | 0.7% | $4,905 | $1.81 | 2,710 | 391,628 | 09 Dec 2025 | Direct |
| Paul Stuka | NSPR | Common Stock | Purchase | 1.32% | $9,436 | $1.86 | 5,073 | 388,918 | 05 Dec 2025 | Direct |
| Paul Stuka | NSPR | Common Stock | Purchase | 2.71% | $18,740 | $1.85 | 10,130 | 383,845 | 04 Dec 2025 | Direct |
| Paul Stuka | NSPR | Common Stock | Purchase | 3.73% | $21,758 | $1.62 | 13,431 | 373,715 | 12 Nov 2025 | Direct |
| Gary S. Roubin | NSPR | Common Stock | Award | 7.89% | 48,000 | 656,425 | 07 Oct 2025 | Direct | ||
| Thomas J. Kester | NSPR | Common Stock | Award | 8.99% | 37,815 | 458,573 | 15 Sep 2025 | Direct | ||
| Thomas J. Kester | NSPR | Options to purchase common stock (right to buy) | Award | 19,041 | 19,041 | 15 Sep 2025 | Direct |
* marks a reported price that did not pass the local price check.